Efficacy of albuterol –budesonide asthma rescue inhaler in adults with moderate-to-severe asthma with exercise as a trigger: post-hoc sub-group analysis of MANDALA
Albuterol-budesonide 180/160 μg inhaler is FDA approved for as-needed treatment or prevention of bronchoconstriction and to reduce exacerbation risk in patients aged ≥18 years with asthma. In MANDALA (NCT03769090), as-needed albuterol-budesonide 180/160μg reduced severe exacerbation risk by 28% versus albuterol in symptomat ic patients ≥18 years with moderate-to-severe asthma on a wide variety of inhaled corticosteroid (ICS)-containing maintenance therapies. Exercise is a well-recognized trigger of asthma symptoms/deterioration.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Elliot Israel, Bradley Chipps, Richard Beasley, R. Panettieri, Sam Bardsley, Christy Cappelletti, Lynn Dunsire, Ileen Gilbert, Tim Harrison, Frank Trudo, Alberto Papi Source Type: research
More News: Albuterol | Allergy | Allergy & Immunology | Asthma | Corticosteroid Therapy | Israel Health | Middle East Health | Proair HFA | Sports Medicine | Ventolin